Cell fate perturbations underlie many human diseases, including breast cancer 1,2 . Unfortunately, the mechanisms by which breast cell fate are regulated are largely unknown. The mammary gland epithelium consists of differentiated luminal epithelial and basal myoepithelial cells, as well as undifferentiated stem cells and more restricted progenitors 3, 4 . Breast cancer originates from this epithelium, but the molecular mechanisms that underlie breast epithelial hierarchy remain ill-defined. Here, we use a highcontent confocal image-based short hairpin RNA screen to identify tumour suppressors that regulate breast cell fate in primary human breast epithelial cells. We show that ablation of the large tumour suppressor kinases (LATS) 1 and 2 (refs 5, 6), which are part of the Hippo pathway, promotes the luminal phenotype and increases the number of bipotent and luminal progenitors, the proposed cells-of-origin of most human breast cancers. Mechanistically, we have identified a direct interaction between Hippo and oestrogen receptor-α (ERα) signalling. In the presence of LATS, ERα was targeted for ubiquitination and Ddb1-cullin4-associated-factor 1 (DCAF1)-dependent proteasomal degradation. Absence of LATS stabilized ERα and the Hippo effectors YAP and TAZ (hereafter YAP/TAZ), which together control breast cell fate through intrinsic and paracrine mechanisms. Our findings reveal a non-canonical (that is, YAP/TAZ-independent) effect of LATS in the regulation of human breast cell fate.
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We have developed a high-content image-based short hairpin RNA (shRNA) screen (Supplementary Table 1 and Extended Data Fig. 1a ) to identify regulators of breast epithelial cell fate. We cultured unpassaged primary human breast epithelial cells (PHBECs) as non-adherent mammospheres that are enriched in stem and progenitor cells 7 , infected them with a tumour suppressor shRNA library, and quantified the number and size of spheres and the fractions of basal keratin (KRT)14
luminal KRT19
+ , and KRT14 + KRT19 + double-positive progenitor cells 8 in the spheres (Extended Data Fig. 1b and Supplementary Table 2 ). shRNAs targeting regulators of the Hippo pathway (LATS1, LATS2, FAT1 and FAT3) scored highly for inducing increased sphere formation and the number of KRT14 +
KRT19
+ cells (Fig. 1a and Supplementary  Table 3) .
shRNAs targeting these genes increased the fractions of double-positive and luminal KRT19 + cells (Extended Data Fig. 1b, c  and Supplementary Tables 2, 3 ). In the human breast, KRT14 and KRT19 mark not only bipotent cells but also luminal progenitors 4, 9, 10 , which also exhibit high sphere-forming capacities and have been suggested to harbour the cells-of-origin of most breast cancers 9, 11 . LATS knockdown increased the self-renewal capacity of human and mouse primary unpassaged mammary cells, and yielded a higher number of KRT19
+ and KRT14 + KRT19 + PHBECs but fewer KRT14 + cells than in controls (Fig. 1b, c and Extended Data Fig. 1d, e) . Similarly, LATS knockdown in MCF10A cells enhanced self-renewal, decreased the number of KRT14
+ cells and increased the number of KRT18 + and KRT14 + KRT18 + cells (Extended Data Fig. 1f-h ). Introduction of LATS1 cDNA to MCF10A cells expressing a shRNA targeting the LATS1 3′ UTR (shLATS1C) reversed the phenotype of LATS knockdown and excluded potential off-target effects (Extended Data Fig. 1i) .
Characterization of the effects of LATS on global gene expression and breast lineage profiles showed that the shLATS-treated PHBEC samples clustered together irrespective of donor identity, overlapped with previously published profiles of normal luminal breast progenitor and mature luminal cells 12 , and were enriched for genes that are downregulated in normal basal breast cells and in genes associated with ERα + breast cancers 13, 14 ( Table 4) .
It has been shown that LATS ablation stabilizes the transcriptional co-activators YAP/TAZ, which have been reported to promote basal lineage commitment in breast development 15, 16 and to induce epithelialto-mesenchymal transition, the cancer-stem-cell phenotype, and tumour progression [17] [18] [19] [20] . Our finding, that LATS knockdown promotes a luminal phenotype, seems paradoxical in the light of the reported effects of YAP/TAZ. To resolve this paradox and identify transcription factors that direct PHBECs lacking LATS towards a luminal phenotype, we used a computational method (ISMARA) 21 to model transcription factor activity. The activities of ERα and other luminal regulators 22 were higher in shLATS-treated than in non-targeting shRNA control (shNT)-treated PHBECs ( Fig. 2b and Extended Data Fig. 2g ). The mRNAs of ERα , c-KIT (a marker for luminal progenitors 9, 11, 23 ) and of several ERα targets were upregulated upon LATS removal (Extended Data Fig. 2h ). LATS knockdown also increased luminal and luminal progenitor markers and slightly decreased basal markers at the protein level ( Fig. 2c and Extended Data Fig. 2i ). LATS knockdown decreased phosphorylation of the YAP-Ser127 inhibitory site and increased YAP/TAZ protein levels. Notably, this stabilization of YAP/TAZ upon LATS removal only modestly upregulated CTGF and Cyr61 (downstream targets of YAP/TAZ), and we found no enrichment of YAP/TAZ-driven gene sets when the shLATS PHBEC expression profile was overlapped with datasets of YAP/TAZ targets 19, 24, 25 (Extended Data Fig. 3a, b) . Next, we assessed the relative contributions of the two activated signalling branches, the canonical YAP/TAZ branch and the non-canonical ERα branch, to the activation of the luminal gene signature and the increase in sphere formation in cells lacking LATS. Ablation of LATS1 and 2 in MCF10A cells recapitulated the effects observed with PHBECs, regarding both the global transcriptome and the phenotype of the Table 5 ). The transient overexpression of YAP/TAZ and/or ERα to levels comparable to those seen in shLATS-treated cells showed that activation of both signalling pathways is required to phenocopy the effects of LATS ablation. Exogenous expression of only YAP/TAZ enriched YAP/TAZ signatures, which validated this approach ( Fig. 2d and Extended Data Fig. 5a, b) . Next, we inhibited endogenous YAP/TAZ and ERα in shNTand shLATS-treated MCF10A cells using small interference (si)RNA and assessed the effects on luminal markers and sphere formation. Although sphere-forming capacity was almost fully reversed by siRNAs targeting both YAP and TAZ, this knockdown only partially reduced induction of luminal markers in shLATS-treated cells. Inhibition of ERα , on the other hand, only partially reversed the enhanced sphere-forming capacity of shLATS-treated cells but fully abrogated the upregulation of luminal markers (Extended Data Fig. 5c-e) . Notably, ablation of both YAP/TAZ and ERα signalling in shLATS-treated cells fully reversed the increase in sphere-forming capacity and the expression of luminal markers ( Fig. 2e and Extended Data Fig. 5f ).
Amphiregulin (AREG) is regulated by both ERα and YAP/TAZ 26 . AREG secretion increased in shLATS-treated cells and depletion of both YAP/TAZ and ERα reduced AREG mRNA levels in shLATS-treated cells to the levels of shNT-treated controls (Extended Data Fig. 5g ). 
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An antibody blocking AREG decreased sphere-forming capacity in shLATS-treated relative to shNT-treated cells. Conditioned medium from LATS-knockdown cultures enhanced the number of spheres formed by MCF10A cells, an effect that was prevented by the AREGblocking antibody (Extended Data Fig. 5h ). Thus, ERα mainly enhances the expression of luminal markers and contributes via AREG to increased sphere formation. In turn, YAP/TAZ mostly increase sphere formation and contribute partially to the increase in luminal markers (Extended Data Fig. 5i ).
As expected, LATS knockdown increased proliferation and survival 27 (Extended Data Fig. 6a-e) . Hence, the increased luminal phenotype in total breast epithelial cells lacking LATS could result from expansion of the luminal ERα + cells. In co-cultures of labelled cells expressing ERα and/or LATS in suspension, ERα + cells lacking LATS outcompeted the other cells, an effect that was reversed by depletion of YAP/TAZ (Extended Data Fig. 6f, g ). This suggests that there is YAP/TAZ-dependent expansion of ERα + cells in the absence of LATS.
Notably, analysis of LATS1 expression in normal breast tissue, PHBECs or breast tumours revealed that LATS1 was mostly nuclear in basal cells and cytoplasmic in luminal cells (Extended Data Fig. 7a ). We investigated the effects of LATS in subpopulations of cells 9 sorted by fluorescence-activated cell sorting (FACS) (Fig. 3a and Extended Data Fig. 7b ). LATS ablation in luminal mature and progenitor cells led to enhanced sphere and colony formation (Fig. 3a) , which is in line with the observed increase in the fraction of these subpopulations (Extended Data Fig. 7c ). Although the loss of LATS in basal cells had no effect on sphere or colony numbers, the number of luminal (KRT19 and mature luminal cells. However, there was only a slight increase in downstream targets of YAP/TAZ, which were already expressed at higher levels than in luminal cells 15, 16 ( Fig. 3a and Extended Data Fig. 7e ). These subpopulation-specific effects of LATS removal were also observed in subpopulations of mouse mammary cells sorted by FACS (Extended Data Fig. 7f, g ).
In an assay quantifying the regenerative potential of PHBECs ex vivo 28 , shLATS-treated cells seeded on floating collagen gels formed more multisphere-like terminal ductal lobular units and spheres, which originate from luminal progenitors, than control cells, but fewer terminal ductal lobular units, which arise from the basal compartment ( Fig. 3c and Extended Data Fig. 7h ). Next, we ablated Lats1 and 2 in primary mouse epithelial cells and injected different numbers of cells into cleared mammary fat pads. Notably, cells depleted of Lats formed no outgrowths (Fig. 3d) . Transcriptional profiling of the cells before injection showed higher levels of luminal and luminal progenitor markers and lower levels of basal and mouse mammary stem-cell activity markers in shLats cells (Extended Data Fig. 7i) .
Our results show that LATS ablation in breast epithelial cells expands luminal and bipotent progenitors and enhances differentiation along the luminal lineage at the expense of basal progenitors and basal cells. This results in a population of cells with high sphere-forming capacity, low mammary repopulating activity and a luminal phenotype (Extended Data Fig. 7j) .
The pronounced upregulation of ERα protein upon removal of LATS contrasts with a modest increase in ERα mRNA (Fig. 4a) , which prompted us to investigate whether LATS regulates ERα protein levels directly. We used luminal human breast cancer cells, because they express ERα endogenously and are amenable to experimental manipulation. Removal of LATS upregulated ERα protein and target genes. Expression of either full-length LATS1 or LATS1 lacking the kinase domain decreased ERα levels and reversed the upregulation of luminal genes in shLATS-treated cells ( Fig. 4b and Extended Data Fig. 8a-c) , suggesting that the kinase activity of LATS1 is dispensable for ERα regulation. Following inhibition of translation, LATS knockdown increased the half-life of ERα protein upon stimulation with oestrogen and this effect was dependent on proteasomal degradation of ERα (Extended Data Fig. 8d , e). Given that ubiquitination of ERα precedes its proteasomal degradation and that the LATS1 mutant that induced downregulation of ERα protein contains an N-terminal ubiquitinassociated domain, we tested whether ubiquitination of ERα is reduced in the absence of LATS and found this to be the case (Extended Data  Fig. 8f) .
To delineate the mechanism by which LATS degrades ERα , we performed ERα immunoprecipitation followed by quantitative proteomics. The ubiquitin-ligase substrate receptor DCAF13, a member of the DDB1 and CUL4-associated factors (DCAF) protein family, was decreased in ERα immunoprecipitation assays of cells lacking LATS ( Fig. 4c and Supplementary Table 5 ). DCAF1 has recently been shown to interact with LATS1 (ref. 29) and our co-immunoprecipitation experiments showed a protein complex consisting of LATS1, DCAF1, DCAF13 and ERα (Fig. 4d) . Notably, DCAF13 expression was reduced and DCAF1 was completely absent in ERα complexes from cells lacking LATS, and depletion of DCAF1 in cells exogenously expressing LATS1 prevented ubiquitination and degradation of ERα (Fig. 4d , e and Extended Data Fig. 8g ). These findings suggest that LATS1-dependent degradation of ERα requires the presence of DCAF1 and support a model in which the N-terminal domain of LATS1 acts as an adaptor that brings together a complex containing LATS1, ERα and DCAF1 (Fig. 4f) .
Analysis of human primary breast tumours and cell lines showed barely detectable LATS1 protein expression, which correlated negatively with ERα levels in primary tumours, and LATS1 protein levels were low or not detected in 75% of basal and in all luminal breast cancer lines compared to MCF10A cells (Extended Data Fig. 9a ). This is consistent with the effects of LATS1 on downregulation of ERα levels that we discovered in normal mammary cells.
Next, we investigated whether loss of LATS affects proliferation, tumour growth or treatment response in ERα + breast cancer models. Downregulation of LATS in T47D and MCF7 cells reduced sensitivity to fulvestrant but had no effect on untreated or tamoxifen-treated cells. Consistently, fulvestrant failed to degrade ERα or to reduce the tumour growth of cancer cells lacking LATS (Extended Data Fig. 9b , c). These findings suggest that loss of LATS in luminal breast cancer models stabilizes ERα and results in resistance to treatments targeting the downregulation of ERα . Analysis of publically available datasets 30 showed that low expression of LATS1 and 2 is associated with reduced relapse-free survival of patients with breast cancer treated with anti-oestrogen therapy but not of patients treated with tamoxifen only. The opposite trend was observed in patients with ERα -negative breast cancer, in whom higher levels of LATS1 and 2 tended to be associated with lower relapse-free survival (Extended Data Fig. 9d ), possibly by contributing to lower ERα levels and consequently higher aggressiveness of the disease.
The Hippo tumour suppressor pathway is a universal governor of organ size and controls cell fate. The effects of upstream LATS, which phosphorylate and inhibit the canonical Hippo pathway transcriptional co-activators YAP/TAZ, have remained unclear, as has the question of whether these kinases regulate other pathways. Here we report that LATS controls cell fate in the normal breast by differential effects in luminal and basal cells and show non-canonical crosstalk between the Hippo pathway and ERα signalling (Extended Data Fig. 10 ). We discov- The fact that a lack of LATS results in YAP/TAZ stabilization but promotes a breast luminal phenotype may seem paradoxical in the light of previous studies showing that YAP/TAZ expression is associated with a basal fate 15, 16 and challenges the view that inactivation of Hippo signalling systematically enhances stemness 19, 27 . Unlike previous studies that overexpressed YAP/TAZ, we inactivated Hippo signalling by ablating the upstream kinase LATS. This results in stabilization of both ERα and YAP/TAZ and, thus, resolves this apparent paradox. Indeed, the net result of ERα and YAP/TAZ stabilization after LATS knockdown promotes luminal differentiation and depletes mammary repopulating capacity. This provides a cell-autonomous explanation for the previously observed lack of mammary glands in Lats1-knockout mice 31 . Our demonstration of non-canonical crosstalk between Hippo and ERα signalling may have far-reaching implications beyond the mammary gland, as oestrogen signalling is important in almost all tissues 32 . Supplementary Information is available in the online version of the paper.
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Primary human cell culture. For the 3D breast cell fate screen, breast tissues were collected from women undergoing reduction mammoplasties and handled and maintained according to protocols approved by the GNF Biomedical Institutional Review Board. To isolate single PHBECs, primary breast samples were mechanically dissociated and digested in serum-free mammary epithelial growth medium (MEGM, Lonza) containing 200-300 U ml −1 collagenase (Worthington), treated with 0.25% trypsin for 1-2 min, 1× red-blood-cell lysis buffer for 3 min, and then filtered through cell strainers. The dissociated single PHBECs were cultured to generate mammospheres in modified serum-free MEGM medium supplemented with 20 ng ml −1 bFGF (Invitrogen), 20 ng ml −1 EGF (Invitrogen), 0.5× B27 (Invitrogen), 4 μ g ml −1 heparin (Sigma), 2 mM l-glutamine (Invitrogen), 5 μ g ml −1 insulin (Sigma), and 10 −6 M hydrocortisone (StemCell Technologies). Bovine pituitary extract was excluded from the MEGM kit.
For all the follow-up experiments, fresh reduction mammoplasty tissue samples obtained with appropriate informed consent were used to isolate PHBECs according to previously published protocols [33] [34] [35] . Approval for culture of reduction mammoplasty tissue was granted by the Ethics Commission Beider Basel (EKBB). Breast epithelial cells were cultured in M5 medium, which we have previously shown to allow the propagation of undifferentiated epithelial precursor cells in suspension and their differentiation along the two breast epithelial lineages 33 . M5 medium comprises 50% M199 medium (Amimed, Bioconcept), 50% F12 (Sigma) supplemented with 20 ng ml −1 EGF (PeproTech), 1× B27 (Gibco, Invitrogen), 1 nM 17-β -oestradiol, 57 μ M β -mercaptoethanol, 15 mM HEPES (Sigma), and 1× penicillin/streptomycin (Gibco, Invitrogen). M5 was used for all experiments with PHBECs. Modified polystyrene culture plates (BD, Falcon Primaria) were used for monolayer colony formation and differentiation assays of PHBECs. Between 500 and 2,000 cells were seeded per well in 6-well plates and grown in M5 medium for 7-10 days before fixation or lysis. For 3D-sphere-formation assays, 2,000-10,000 cells per ml were grown in ultra-low attachment dishes (Corning) for 6-10 days. For floating collagen gel assays 28 , single-cell suspensions were quickly mixed with neutralizing solution and acidified rat-tail collagen I (Corning) was added, to a final concentration of 1.3 mg ml . The gel mixture was plated into siloxane-coated 24-well plates at a density of 2 × 10 4 cells per gel. After polymerization of the gel, medium with supplements was added and gels were detached from the well. Cells were initially cultured for 5 days in mammary epithelial cell growth medium (MECGM, PromoCell) supplemented with 1% penicillin/streptomycin (Invitrogen), 0.5% FCS (Pan Biotech), 3 μ M Y-27632 (Biomol) and 10 μ M forskolin (Biomol). The medium was replaced with M5 medium for the following 7 days of culture. All primary cells were cultured at 37 °C in a humidified 5% CO 2 , 5% O 2 controlled incubator. 3D breast cell fate screen. PHBECs were plated at a cell density of 3,000 cells per well in a 384-well plate. After 24 h, the PHBECs were spin-transduced at 1,800 r.p.m. for 1 h with lentivirus carrying a tumour suppressor shRNA library targeting 77 genes, each represented by 3-5 different shRNAs (Supplementary Table 1 ). The PHBECs were selected 24 h after transduction by 0.4 μ g ml −1 puromycin. After 10 days of culture (at day 13), the PHBEC-derived mammospheres were fixed in ice-cold MeOH for immunofluorescence staining and high-content confocal imaging. Anti-KRT14 (Abcam, LL002, IgG3) and anti-KRT19 (Abcam, A53-B/A2, IgG2a) were used as primary antibodies (at day 13), and Alexa Fluor 488-anti-mouse IgG3 and Alexa Fluor 633-anti-mouse IgG2a were used as secondary antibodies (at day 14). The automated 'bottle valve' dispenser at GNF was used for medium/reagent addition and removal via aspiration. High-content confocal imaging and redundant shRNA activity analysis. Mammospheres were examined in a 384-well plate by immunofluorescence staining and high-content confocal imaging using an Opera High Content Screening System (PerkinElmer). The plate was imaged at a resolution of 20× and three optical sections separated by 30 μ m were collected. Optical sectioning was optimized to avoid collecting identical cells in different optical sections. In each well, 63 fields were collected for three different z sections (total, 189 images per well). A custom analysis using Acapella was performed on the images as follows: (1) assembly of the different image planes (collating the different images into a single image); (2) detection of cell nuclei using DAPI staining in each plane; (3) detection of cell boundaries using low level DAPI fluorescence; (4) detection of individual spheres as a group of cells in 3D (that is, cells in different planes are associated with the containing sphere object); (5) association of cells from different planes to a given 3D sphere; (6) classification of cells as KRT14 and/or KRT19 positive/negative in each sphere (and across each plane); and (7) calculation and output of sphere and cellular statistics (for example, number, area, fraction of KRT14/KRT19 positive). In the downstream analysis, only spheres with more than 20 cells were selected for processing. The features extracted from the image data were then processed using redundant shRNA activity analysis (RSA), which allows computation of statistical scores that model the probability of a gene 'hit' based on the collective activities of multiple shRNAs per gene 36 . In particular, the number of spheres and the fraction of KRT14/KRT19 double-positive cells present in the spheres or in total cells were selected as biologically meaningful features. The genes were then ranked on the basis of the RSA scores. RSA P values were calculated from the activity of the different shRNAs and the reproducibility of these activities across the multiple shRNAs available for each gene. Lentiviral vectors, lentivirus production and infection. For human LATS knockdown, the following TRC pLKO clones (Sigma) were used: LATS1A, NM_004690.x-2666s1c1; LATS1B, NM_004690.x-3614s1c1; LATS1 + 2, NM_014572.x-2894s1c1; LATS1C, NM_004690.x-4412s1c1; and the MISSION Non-Target shRNA Control Vector SHC002 (shNT). For mouse Lats knockdown, Lats1, NM_010690.1-878s21c1 and Lats2, NM_015771.2-660s21c1 were used (both Sigma). For the competition experiment, GFP-and ERα -expressing lentiviral vectors were cloned as described 37 . Lentiviruses were produced by PEI transfection of 293T cells as described 33, 38 . The titre of each lentiviral batch was determined in PHBECs, FVB MECs or MCF10A cells. Primary human and mouse cells were infected in suspension for 8 h or overnight, respectively. Cell lines were infected overnight in the presence of hexamethrine bromide (8 μ g ml −1 ). Infections were performed at a multiplicity of infection of 5-10 viral particles per cell. Selection with 1.25-1.5 μ g ml −1 puromycin was applied 48 h after infection. Animal and unsorted MECs experiments. Female severe combined immunodeficient (SCID)/beige and severe combined immunodeficient/non-obese diabetic (SCID/NOD) (Jackson Labs) and friend virus B (FVB) mouse colonies were maintained in the animal facility of the Friedrich Miescher Institute for Biomedical Research in accordance with Swiss guidelines on animal experimentation. Experiments were performed in accordance with the Swiss animal welfare ordinance and approved by the cantonal veterinary office of Basel Stadt. For preparations of single mammary cell suspensions, mammary glands were dissected and intra-mammary lymph nodes removed. To obtain mammary organoids, mammary glands were processed as described previously 39 . To obtain single mammary epithelial cells, organoids were washed in serum-free Leibowitz L15-medium (Gibco) and digested with Hyclone HyQTase (Thermo Scientific). Single cells were washed, filtered through a 40-μ m cell strainer (BD Falcon) and counted. Mammosphere cultures were performed as described previously 40 . Freshly digested MECs were plated at 20,000 cells per ml in 6-well ultra-low attachment plates (Falcon) in DMEM/F12 medium (Gibco) supplemented with 5 μ g ml −1 insulin, 0.5 μ g ml −1 hydrocortisone, 2% B27 (Invitrogen), 20 ng ml −1 EGF and bFGF (BD Biosciences) and cholera toxin (Sigma), and cultured at 37 °C in 5% CO 2 . After 6-7 days, mammospheres were collected, counted, dissociated into single cells using HYQtase (Gibco) and re-seeded. For limiting dilution transplantation, shNTand shLats1 + 2-passage spheres were dissociated, resuspended in PBS + 2% FCS with 25% basement membrane matrix (growth factor reduced; BD, 356230) and injected in 20-ml aliquots into inguinal glands of 3-week-old FVB females that had been cleared of endogenous mammary epithelium. Cells from control (shNT) and from shLats1 + 2 spheres were injected into the same animals on opposite sides. After 10 weeks, glands of the recipients were removed, spread on a glass slide and fixed in Carnoy's fixative overnight. Whole-mount staining with carmine alum was performed as previously described 41 and the tissue was scanned with an Epson 1600 Pro scanner. An outgrowth was defined as an epithelial structure composed of ducts arising from a central point with lobules and/or terminal end buds. The frequencies of mammary-repopulating units in the different conditions were calculated and statistically compared using the Extreme Limiting Dilution Analysis (ELDA) 42 online tool (http://bioinf.wehi.edu.au/software/elda/). For orthotopic engraftment of breast cancer cell lines, 2 × 10 6 T47D cells were suspended in a 100-μ l mixture of basement membrane matrix phenol red-free (BD Biosciences) and PBS (1:1) and injected into the fourth mouse mammary gland of 6-8-week-old female SCID/beige and SCID/NOD mice. Mice received oestrogen-containing drinking water 2 days before injection. Tumour-bearing mice were randomized on the basis of tumour volume before the initiation of treatment, which started when average tumour volume was at least 250 mm 3 . Fulvestrant dissolved in sunflowerseed oil (both from Sigma) was injected intraperitoneally as indicated. Tumours were measured every 3-4 days with Vernier calipers and tumour volumes calculated by the formula 0.5 × (larger diameter) × (smaller diameter)2. Mice were euthanized before the maximal tumour volumes permitted, as approved by cantonal veterinary office of Basel Stadt (1,500 mm 3 ), were reached. Cell lines and in vitro experiments. All cell lines were from ATCC and cultured according to their protocols, except for the immortalized but untransformed human breast epithelial cell line MCF10A 43 which was maintained as previously described 44 . Cell line identity was confirmed by short tandem repeat (STR) sequencing and all cell lines were routinely tested for mycoplasma contamination. For most experiments, MCF10A cells were cultured in M5 medium and the Letter reSeArCH medium refreshed or replaced every 3 days. Antibody-blocking experiments were performed by adding anti-AREG (R&D, MAB262, 0.5-10 μ g ml
) or a mouse IgG antibody (R&D, 10 or 2.5 μ g ml −1 ) to the medium before seeding of the cells or transferring the conditioned medium. Cell viability was measured using the cell proliferation reagent WST-1 (Roche). Colony-formation assays were performed by seeding 500-1,000 cells per well in 6-well plates. Cells were allowed to adhere overnight before treatment with inhibitors or solvent as indicated. Colonies were stained after 6-10 days with 0.2% crystal violet in PBS/4% formalin. Colony area was quantified using the Odyssey scanner and software (LICOR) or ImageJ (FIJI, 64 bit). For sphere-formation assays, 4,000 (passage 1) or 1,000 (subsequent passages) MCF10A cells per ml were grown in ultra-low attachment dishes (Corning) for 5-7 days. For LATS1 overexpression experiments, the following plasmids were used (Addgene): LATS1 wild-type, p2× Flag CMV2 LATS1 (Plasmid 18971), LATS1 mutant/kinase-truncated = p2× Flag CMV2 LATS1-N-mutant (Plasmid 18976) as well as the pFlag CMV2 empty vector control. Cells were transiently transfected using Lipofectamine2000 according to the manufacturer's protocol (Life Technologies). Transient gene silencing. siRNAs were ordered as reversed-phase highperformance liquid chromatography purified duplexes (Silencer Select, Invitrogen). The siRNA IDs were as follows: siYAP (s20366 and s20368), siTAZ (s13807 and s13806), siERα (s4823 and s4825), Silencer Select negative control siRNA (siNT; AM4611). siRNAs against DCAF1 (L-021119-01-0005) and non-targeting controls (D-001810-10-05) were ordered as onTarget-plus SMART pools (Dharmacon). Transfections of siRNAs were performed according to the manufacturer's guidelines (DharmaFect 1, Dharmacon). Compounds and formulations. For the luminal breast cancer subtype, the most commonly used treatments are fulvestrant and tamoxifen 45 . Fulvestrant, 4-hydroxytamoxifen (4-OHT), tamoxifen (OHT), cycloheximide and MG132 were from Sigma. Fulvestrant and MG-132 were prepared as 10 mM stock solutions in DMSO and 4-OHT and cycloheximide at 10 mM in ethanol and stored at − 20 °C. For in vivo studies, fulvestrant was dissolved in sunflower seed oil (Sigma) and injected intraperitoneally as indicated. , Sigma) was added at a final concentration of 1 μ g ml −1 . For all experiments, at least 10 4 cells per sample were analysed with a FACScan flow cytometer BD FACSCalibur or BD LSR II SORP (Becton Dickinson). For sorting of cells from normal mouse mammary epithelium, mammary glands were dissected and intra-mammary lymph nodes removed. To obtain mammary organoids, mammary glands were processed as described previously 39 . To obtain single mammary epithelial cells, organoids were washed in serum-free Leibowitz L15-medium (Gibco) and digested with Hyclone HyQTase (Thermo Scientific). Single cells were washed and filtered through a 40-mm cell strainer (BD Falcon) and counted; 10 6 cells per ml were stained with the following antibodies: PE/Cy7-CD45 (Biolegend, clone 30-F11), APC-Sca1 (Biolegend, clone E13-161.7), PerCP/Cy5.5-CD24 (Biolegend, clone M1/69), PE-CD49f (BD-Pharmingen) and DAPI (2 mg ml −1 , Invitrogen). FACS was carried out in a BD FACSAria III (Becton Dickinson) using a 100-mm nozzle. Cells were gated on the basis of their forward and sideward-scatter. Pulse-width was used to exclude doublets. DAPI
− cells were then gated for CD24, Sca1 and CD49f subsets. FACS data were analysed using FlowJo (Tree Star). We used CD24 and Sca1 markers to separate basal (CD24 39, 46 and the purity of the fractions was assessed by immunofluorescence staining of cytospun single cells for luminal and basal keratins immediately after sorting. MECs in vitro colony-formation assay and immunofluorescence imaging. Freshly sorted cells of each subpopulation (1,000-7,500 cells) were plated as previously described 41 . Seven (luminal cells) or ten (basal cells) days later, the colonies were fixed with acetone/methanol (1:1), washed, blocked with 2.5% normal goat serum and stained with anti-keratin 8/18 (guinea pig, 1:500, Fitzgerald, 20R-CP004), anti-keratin 14 (rabbit, 1:500, Thermo Scientific, Rb9020), DAPI (2 μ g ml −1 , Invitrogen), anti-guinea-pig Alexa Fluor 488 and anti-rabbit Alexa Fluor 647 (1:500, Invitrogen). Images of stained sections were captured using the Yokogawa CellVoyager 7000S (CV7000S) high-content-screening system with a micro-lens enhanced confocal Nipkow spinning disk CSU-W1 scanner unit (10× magnification, NA = 0.4) and a sCMOS camera (2,560 × 2,160 pixels). Images were stitched using ImageJ software. Colonies were defined as a cluster of more than five cells. Colonies containing more than 20% of keratin 8/18 and keratin 14 doublepositive cells were defined as 'double-positive' . Immunoblotting, immunoprecipitation assays and mass spectrometry. Cells for immunoblotting and ELISA were lysed with RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS), supplemented with 1× protease inhibitor cocktail (Complete Mini, Roche), 0.2 mM sodium orthovanadate, 20 mM sodium fluoride, and 1 mM phenylmethylsulfonyl fluoride. For ERα immunoprecipitation assays, nuclear cell lysates (NE-PER Nuclear and Cytoplasmic Extraction Reagents, Pierce, 78833, plus 4 M Urea) containing 250-500 μ g protein were incubated with 1 μ g antibody and 20-50 μ l protein A-sepharose beads (Zymed Laboratories) overnight at 4 °C. Whole-cell lysates, immunoprecipitates or nuclear cell lysates (30-80 μ g) were subjected to SDS-PAGE, transferred to PVDF membranes (Immobilon-P, Millipore), and blocked for 1 h at room temperature with 5% milk in PBS-0.1% Tween 20. Membranes were then incubated overnight with antibodies as indicated and exposed to secondary HRP-coupled anti-mouse or -rabbit antibody at 1:5,000-10,000 for 1 h at room temperature. For each of the blots presented, the results shown are representative of at least three independent experiments. The following antibodies were used: LATS1 (Cell Signaling, 9153 and 3477, 1:1,000), LATS2 (Abcam 1:500), LATS2 (Cell Signaling, 13646, 1:500), ERK2 (Santa Cruz, 1:2,000), pYAP (Ser127, Cell Signaling, 1:1,000), YAP/TAZ (Cell Signaling, 1:1,000), CCND1 (Santa Cruz, sc-718, 1:500), PCNA (Cell Signaling, 1:2,000), c-KIT (Cell Signaling, 1:400), ERα (Thermo/Fisher Scientific, clone SP1, 1:500), ERα (Cell Signaling, 8644, 1:500), keratin 18 (KRT18, Thermo Scientific, MS-142, 1:1,000), keratin 14 (KRT14, Thermo Scientific, RB-9020, 1:2,000), keratin 19 (KRT19, Thermo Scientific, MS-198, 1:1,000), BMI-1 (Millipore, 05-637, 1:500), GFP (MBL, LabForceAG, 598), PARP (Cell Signaling, 1:1,000), phosphorylated ERα (Ser118, Santa Cruz, sc-12915), mono/poly-ubiquitin antibody (Enzo Life Sciences, clone FK2, BML-PW8810-0100, 1:1,000), DCAF1 (Novus, NBP1-05953) and DCAF13 (Abcam, ab83546).
Quantitative analysis of immunoprecipitates was performed using isobaric tagging with the iTRAQ reagent (Applied Biosystems) as described previously 47 . In brief, for each analysis four immunoprecipitates were separated by SDS-PAGE on 4-12% NuPage Gels (Invitrogen). After staining with colloidal Coomassie blue, the four gel lanes were excised in 16 equally sized slices and in-gel digested with a trypsin/Lys-C mix (Promega). The peptide eluates were labelled with iTRAQ reagent, using a different reagent for each lane. After labelling, peptides from corresponding bands of four lanes were pooled, dried and resuspended for liquid chromatography-mass spectrometry analysis. Liquid chromatography-mass spectrometry was performed using an Orbitrap Elite mass spectrometer equipped with an EasyLC 1000 nanoUPLC system. Peptides were loaded on a 2 cm × 100 μ m trap column (Thermo Easycolumn) and then separated on a homemade 15 cm × 75 μ m analytical column filled with Magic 3-μ m 100-Å C18 AQ (Michrom, Auburn, CA), using a 60-min gradient from 2-30% acetonitrile in water with 0.1% formic acid at a flow rate of 250 nl min . Tandem mass spectra were acquired in a data-dependent manner, in which each full scan was followed by sequential collision-induced dissociation and higher-energy collisional dissociation tandem mass spectometry measurements of up to ten most intense precursors. Mass-spectrometry data were analysed and quantified using Proteome Discoverer 2.1 (Thermo Scientific) using a human UniProt database (release April 2013). Peptide and protein indentities were filtered at a 1% FDR against a reversed database.
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Immunofluorescence, microscopy and image analysis of human cells. Cells were fixed with ice-cold methanol/acetone (50/50 v/v) for 10 min at room temperature or with paraformaldehyde (4% in PBS) for 15 min at room temperature. Cells in 3D collagen gels were washed with PBS for 10 min, fixed with 4% paraformaldehyde for 15 min, washed with PBS for 10 min, quenched with 0.15 M glycine for 10 min, and washed again with PBS for 10 min. Then, cells were permeabilized with 0.2% Triton X-100 for 10 min and washed with PBS for 10 min. Cells and cells in collagen gels were blocked with 10% goat serum (Biozol) in 0.1% BSA. The cells or gels were then incubated at 4 °C overnight with the following primary antibodies: keratin 14 (RB-9020, 1:4,000), keratin 18 (MS-142, 1:2,000), keratin 19 (MS-198 1:1,000) ( all Thermo Scientific) or E-cadherin (BD Bioscience, 610181, 1:200). Goat-antimouse, goat-anti-rabbit or goat-anti-guinea pig secondary antibodies coupled to Alexa Fluor 488, 568 or 633 (Molecular Probes, Invitrogen 1:500) were used for detection. Cell nuclei were stained with 167 ng ml −1 DAPI (Sigma) for 10 min. For phase-contrast and fluorescence imaging of cells, images were acquired with an inverted microscope (Nikon Eclipse Ti) using a 10× lens (Nikon Plan Fluor, NA 0.3) and a Nikon Ds-Fi camera. Immunofluorescence staining was analysed with a Zeiss Z1 inverted microscope using a 20× air lens (Zeiss Plan-APOCHROME, NA 0.8) equipped with a motorized Zeiss scanning stage. Axiovision software was used to acquire and stitch images. Confocal images were captured with a LSM-510 confocal microscope (Zeiss) using a 20× air lens (Zeiss Plan-APOCHROME, NA 0.8). Both Zeiss microscopes were equipped with an Axio Cam MRC CCD (6.45 μ m). Percentages of covered area in each colour channel (PHBEC colony formation) and percentages of positive cells (MCF10A colony formation) were quantified using ImageJ (FIJI, 64 bit) software. Immunohistochemistry. Normal tissue was fixed in 10% neutral buffered formalin for 24 h at 4 °C, washed with 70% EtOH, embedded in paraffin, and 3-μ m sections prepared and processed for haematoxylin and eosin staining and immunohistochemistry. Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue sections using a Bond-maX (Leica) fully automated system with anti-LATS1 (Sigma, HPA031804, 1:20).
Tissue microarrays (TMAs) of primary breast cancer tissue samples from 984 patients with breast cancer were selected for this study. The construction of the TMAs and the clinicopathological characteristics of the patient cohort have been described previously 48, 49 . The cohort comprises samples from the Institute of Surgical Pathology of the University Hospital Zürich that were collected between 1991 and 2011. Clinical data, tumour stage, at least 5 years of follow-up and histopathological parameters such as histological grading, hormone receptor and HER2 status were available for all patients. Data regarding the presence of local or distant recurrence were available for most patients. Of the 984 patients with primary breast cancer on the TMAs, 471 could be interpreted and were available for analysis. Two TMAs were used for this study. The first TMA (ZTMA 21) contained 640 single cores from all three subtypes, which were collected from 1991 to 2004. The second TMA (ZTMA 27) contained 344 single cores, which were collected from 1995 to 2004. This retrospective study on human tissue samples was approved by the Cantonal Ethics Committee of Zurich (KEK-2012-553). Informed consent was not necessary, as the ethical approval completely covered all issues of this retrospective study, and the samples were completely anonymized and de-identified before the study. Immunohistochemistry on 4-μ m TMA sections was performed using an automated immunohistochemistry platform from Bond (Vision Biosystems). A rabbit-anti-human polyclonal LATS1 antibody (Sigma, HPA031804) was used at a dilution of 1:50 and pretreatment with CC1 for 44 min. ERα -indices of the cores were calculated by multiplying ERα quantity (0-100%) by ERα intensity (0-3) and cores were grouped into samples with cytoplasmic or nuclear/mixed staining for LATS1. Gene expression profiles. Total RNA was extracted using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen), 100 ng was processed with the Ambion WT Expression Kit (Thermo Fischer Scientific) and 2.75 μ g of the resulting cDNA was fragmented and labelled with the Affymetrix GeneChip WT Terminal Labelling and Hybridization kit (Affymetrix). Following hybridization, non-specifically bound nucleotides were removed by washing and specifically bound target detected using a GeneChip Hybridization, Wash and Stain kit and a GeneChip Fluidics Station 450 (Affymetrix). Hybridization was carried out with 2.5 μ g of biotinylated target, which was incubated with a GeneChip human Gene 1.0 ST Array (Affymetrix) at 45 °C for 16 h. The arrays were scanned using a GeneChip Scanner 3000 7G (Affymetrix) and CEL files acquired using GeneChip Command Console software (Affymetrix). Arrays were normalized and probesetlevel expression values calculated with R/Bioconductor's (v2.15.3/v2.11) affy package using the rma function (https://www.bioconductor.org). Only probe sets annotated with an Entrez Gene according to the hugene10sttranscriptcluster package were selected using the featureFilter function of the genefilter package. Whenever more than one probe set mapped to the same Entrez Gene ID, only the one with the highest IQR was considered. Differential gene expression was determined using linear modelling implemented in the R/Bioconductor package limma. For general analysis, a cutoff of a linear fold change ≥ 2 and adjusted P ≤ 0.01 (corrected with the Benjamini-Hochberg algorithm method) was used. GSEA was performed using the JAVA application from the Broad Institute v2.0 (http://www.broadinstitute. org/gsea). Heat maps show selected luminal progenitor, mature luminal and basal markers according to refs 12, 16, 23 .
For analysis of the The Cancer Genome Atlas data, human breast cancer expression data and corresponding clinical data 50 were obtained from https://tcga-data. nci.nih.gov/docs/publications/brca_2012/, corresponding to the 11 November 2011 data freeze that contains 522 tumour samples with clinical annotation. Only genes with an unambiguous association to an ENTREZ gene identifier were used (Bioconductor package org.Hs.eg.db). If multiple microarray probe sets were associated with a single gene, an arbitrary one was selected to avoid redundant use of data, resulting in a total number of 18,073 genes included in the analysis. Heat map and clustering of the combined expression data was performed using the function aheatmap() from the R package NMF 51 on the top 1,000 genes ranked by variance across human samples. Samples were compared to human PAM50 tumour subtypes (normal, LumA, LumB, Her2 and basal) by calculating Pearson's correlation coefficients of each mouse sample against the averages of all human samples within each subtype. The microarray data from this publication are accessible through GSE61297 and GSE80055. Integrated system for motif activity response analysis (ISMARA). The ISMARA model 21 combines knowledge of gene expression levels (measured by microarray) with transcription-factor-binding sites to answer the question of which transcription factors are driving expression changes. Specifically, log-expression levels of all genes present on the microarray were modelled as linear combinations of transcriptionfactor activities. The coefficients of these combinations were determined by the number of transcription-factor-binding sites in the proximal promoter regions. For each transcription-factor-binding motif m and each sample (microarray) s, the activity A ms with the corresponding error, as well as the significance of activity change of each binding motif were calculated. RNA preparation and qPCR. Total RNA was extracted using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen). 1 μ g of total RNA was transcribed using the Thermo Script RT-PCR System from Invitrogen. PCR and fluorescence detection were performed using the StepOnePlus Sequence Detection System (Applied Biosystems) according to the manufacturer's protocol in a reaction volume of 20 μ l containing 1× TaqMan Universal PCR Master Mix (Applied Biosystems) and 25 ng cDNA. The following probes were used: 1× Taqman Gene Expression Assays (Applied Biosystems) for quantification of 
Statistical analysis.
No statistical methods were used to predetermine sample size. Each value reported represents the mean ± s.d. of at least three independent biological or experimental replicates. Biological replicates are different donors (for example, PHBEC1, 2, 3) or cell models (MCF10As, PHBECs, MECs) or mice. Experimental replicates are either independent experiments or individually treated cells (for example, with compounds, siRNA). Technical replicates are tests or assays run on the same sample multiple times. Data were tested for normal distribution and Student's t-tests (if normally distributed) or nonparametric Mann-Whitney U/Wilcoxon-tests were applied unless stated otherwise. To account for multiple comparisons, Tukey HSD and Wilcoxon tests were performed and adjusted P values are provided. The programs JMP4, JMP9 (SAS) and SPSS (IBM SPSS Statistics for Windows, Version 19.0. Armonk) were used for all statistical tests. P < 0.05 was considered to be statistically significant. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Data availability. Raw data from the primary mammosphere screen are available in Supplementary Tables 1-3 . Proteomics data for Fig. 4 are provided in Supplementary Table 6 . Source Data for Fig. 1b, c, 2e, 3a, c, 4a and Extended Data Fig. 9c are provided with the paper. Microarray data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) database with the accession codes GSE61297 and GSE80055.
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Extended Data Figure 2 | Inhibition of LATS promotes a luminal phenotype. a, Heat map derived from hierarchical clustering of the 182 genes that were differentially expressed between shNT-treated PHBECs (n = 5) and shLATS-treated PHBECs (n = 6). Cut-off: adjusted P < 0.01, fold change > 2.0, expression values > 4. Arrows indicate canonical luminal genes as well as LATS1. b, Principal component analysis (PCA) of microarrays performed on shNT-and shLATS-treated PHBECs. shNT-treated samples cluster separately from both shLATS1B-and shLATS1 + 2-treated samples. c, Venn diagram analysis of differentially regulated genes at a low stringency cut-off of P < 0.05, 2.0-fold change, expression values > 4.0. Both LATS shRNAs show a high degree of overlap when compared to shNT-treated samples and no genes were significantly differentially regulated between cells treated with the two shRNAs. d, shLATS-treated PHBEC expression profiles were significantly enriched in genes that are downregulated in normal basal breast cells. GSEA with shLATS-specific genes and a gene set of normal basal/stem breast cells. shNT-treated PHBECs (n = 5), shLATS-treated PHBECs (n = 6). NES = 2.5; FDR < 0.0001; P < 0.0001. e, shLATS-treated PHBECs express low levels of basal genes. Heatmaps with average normalized expression values of a subset of genes associated with normal basal breast cells. f, Removal of LATS imposes a luminal breast cancer signature on PHBECs. Left, GSEA with shLATS-specific genes derived from PHBECs and gene sets of ERα -positive (left graph) and luminal breast cancer samples (right graph). shNT-treated PHBECs (n = 5), shLATS-treated PHBECs (n = 6). NES = 2.29 (left) and 1.98 (right); FDR < 0.0001; P < 0.0001. Right, clustered heatmap showing correlation coefficients between human breast cancer profiles and shNT-or shLATS-treated PHBECs. g, Graphs of ISMARA transcription factor activity analysis of shLATS-(n = 6) versus shNT-treated (n = 5) PHBECs showing high activity upon removal of LATS for CEBPβ (Z = 1.92; P < 0.0001) and STAT5A,B (Z = 2.184, P < 0.01). h, qPCR analysis of shNT-and shLATS-treated PHBECs. mRNA levels of ERα and c-KIT as well as several canonical ERα -target genes are higher in shLATS-treated PHBECs (n = 6 experimental and 2 technical replicates), i, FACS analysis of PHBECs with LATS knockdown. Markers of luminal progenitors (c-KIT, ALDH activity) and luminal epithelial (EPCAM) cells increased and expression of the basal marker CD10 was reduced upon removal of LATS (n = 6 experimental replicates). Data are mean ± s.d. (h, i); * P < 0.05, * * P < 0.01; NS, not significant.
